Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for kidney size and renal function in ADPKD
IRCT20251007067542N1Phase 3Recruiting
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pioglitazone in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Change in glomerular filtration rate and Change in total kidney volume. Started Dec 2025; status: recruiting.
02
Drugs
pioglitazone
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on IRCT20251007067542N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251007067542N1.